Control and Data Flow Execution of Java Programs

Since decade understanding of programs has become a compulsory task for the students as well as for others who are involved in the process of developing software and providing solutions to open problems. In that aspect showing the problem in a pictorial presentation in a best manner is a key advantage to better understand it. We provide model and structure for Java programs to understand the control and data flow analysis of execution. Especially it helps to understand the static analysis of Java programs, which is an uttermost important phase for software maintenance. We provided information and model for visualization of Java programs that may help better understanding of programs for a learning and analysis purpose. The idea provided for building visualization tool is extracting data and control analysis from execution of Java programs. We presented case studies to prove that our idea is most important for better understanding of Java programs which may help towards static analysis, software debugging and software maintenance

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis

<div><p>Background</p><p>Platinum-based standard chemotherapy improves survival of ovarian cancer (OC), but the five-year survival rate remains below 50%. Antiangiogenic agents (7.5 or 15 mg/kg Bevacizumab, Bev) plus to standard chemotherapy improve progression-free survival (PFS) not overall survival (OS) in completed randomized controlled trials (RCTs). The efficacy and safety of two doses of Bev + standard chemotherapy remain controversial.</p> <p>Methods</p><p>MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane databases and <a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> were searched. The outcomes of eligible RCTs included PFS, OS and toxicities. Hazard ratio (HR) and relative risk (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs).</p> <p>Results</p><p>Bev + chemotherapy improved PFS (HR, 0.82; 95% CI, 0.75 to 0.89; <i>P</i> = .000) and OS (HR, 0.87; 95% CI, 0.77 to 0.99; <i>P</i> = .026) in newly diagnosed OC (2 trials, 2776 patients), and PFS (HR, 0.48; 95% CI, 0.41 to 0.57; <i>P</i> = .000) in recurrent OC (2 trials, 845 patients). Bev + chemotherapy increased non-CNS bleeding (RR, 3.63; 95% CI, 1.81 to 7.29; <i>P</i> = .000), hypertension grade ≥ 2 (RR, 4.90; 95% CI, 3.83 to 6.25; <i>P</i> = .000), arterial thromboembolism (RR, 2.29; 95% CI, 1.33 to 3.94; <i>P</i> = .003), gastrointestinal perforation (RR, 2.90; 95% CI, 1.44 to 5.82; <i>P</i> = .003), and proteinuria grade ≥ 3 (RR, 6.63; 95% CI 3.17 to 13.88; <i>P</i> = .000). No difference was observed between the two Bev doses in PFS (HR, 1.04; 95% CI, 0.88 to 1.24) or OS (HR, 1.15, 95% CI, 0.88 to 1.50), but 15 mg/kg Bev increased toxicities.</p> <p>Conclusion</p><p>Bev + standard chemotherapy delayed progression for newly diagnosed and recurrent OC, and improved survival for newly diagnosed OC. The 7.5 mg/kg dose appeared to be optimal for newly diagnosed OC patients with high risk for progression.</p> </div

Hazard ratios (HRs) of progression-free survival and overall survival.

<p>(A) HRs of progression-free survival for GOG-0218 and ICON7; (B) HRs of progression-free survival for OCEANS and AURELIA; (C) HRs of overall survival for GOG-0218 and ICON7. Bev: bevacizumab; chemo: chemotherapy.</p

Selection process for randomized controlled trials included in the meta-analysis.

<p>Selection process for randomized controlled trials included in the meta-analysis.</p

Progression-free survival by baseline risk factor.

<p>Bev: bevacizumab; chemo: chemotherapy; FIGO: International Federation of Gynecology and Obstetrics; HR: hazard ratio.</p

Comparison of the efficacy and safety of two dose of Bev.

<p>(A) progression-free survival curves; (B) overall survival curves; and (C) toxicity incidence between 7.5 mg/kg and 15 mg/kg Bev. Black <i>P</i>: toxicity incidence between ICON7 and GOG-0218 control arms; red <i>P</i>: toxicity incidence between 7.5 mg/kg and 15 mg/kg bevacizumab + standard chemotherapy arms. ATE: arterial thromboembolism; Bev: bevacizumab; CNS: central nervous system; HR: hazard ratio; GIP: gastrointestinal perforation; OS: overall survival; PFS: progression-free survival; VTE: venous thromboembolism.</p

Table_1_Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.docx

Lymph node (LN) metastasis is a common mode of metastasis in advanced gastric cancer (GC), while axillary LN metastasis infrequently occurs in GC. There are few reports on this rare type of metastasis – especially its clinicopathological features – and systemic treatment are unclear. We describe a case of GC with extensive metastasis, including the rare axillary LN metastasis. The patient achieved partial response of optimal efficacy, who was treated with combination immunotherapy as second-line treatment for nearly two years. The potential mechanisms were revealed by clinical and immune characteristics, such as high expression of PD-L1, high tumor mutational burden (TMB-H), Epstein-Barr virus (EBV) positive and CD8+ tumor-infiltrating lymphocyte positive.</p

Image_1_Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.jpg

Lymph node (LN) metastasis is a common mode of metastasis in advanced gastric cancer (GC), while axillary LN metastasis infrequently occurs in GC. There are few reports on this rare type of metastasis – especially its clinicopathological features – and systemic treatment are unclear. We describe a case of GC with extensive metastasis, including the rare axillary LN metastasis. The patient achieved partial response of optimal efficacy, who was treated with combination immunotherapy as second-line treatment for nearly two years. The potential mechanisms were revealed by clinical and immune characteristics, such as high expression of PD-L1, high tumor mutational burden (TMB-H), Epstein-Barr virus (EBV) positive and CD8+ tumor-infiltrating lymphocyte positive.</p

Additional file 2: of MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

Table S1. Clinical characteristics of the PDAC patients. (DOCX 18 kb

Additional file 1: of MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

Figure S2. The identification of miRNAs. A. The flowchart of miRNA selection and schematic design. B. In the 18 candidate miRNAs, 2 miRNAs were opposite from the miRNA array, 16 were coherent with the miRNA array by Real-time PCR. Good prognosis group/poor prognosis. C. Among the candidate miRNAs, miR-891b and miR-490-5p could inhibit proliferation in cell lines. (PDF 426 kb